ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0761

An Observational Study of Lifetime Prevalence of Thromboembolism Among Patients with Giant Cell Arteritis

Ioannis Koulas1, Nikolaos Tsaftaridis2, Ivana Ilic3, Jack Jnani4, Alex Spyropoulos1 and Lara El Khoury5, 1Feinstein Institutes for Medical Research/Northwell Health, Manhasset, 2Feinstein Institutes for Medical Research/Northwell Health, Manhasset, NY, 3Northwell, Brooklyn, NY, 4Department of Medicine/Northwell Health, Manhasset, 5Division of Rheumatology/Northwell Health, Great Neck, NY

Meeting: ACR Convergence 2024

Keywords: Cardiovascular, giant cell arteritis, Outcome measures, risk factors, Stroke

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Studies indicating a higher incidence rate of stroke and venous thromboembolism (VTE) among patients with giant cell arteritis (GCA) hint at a possible association between GCA and thromboembolic event (TE) risk in general. Most of these studies focus distinctly on either the arterial or the venous component of TEs, while only reporting events around the time of diagnosis. If a higher risk of VTE compared to the general population is indeed present in these patients, direct oral anticoagulants (DOACs), with or without low-dose aspirin, may now offer a safer preventative option compared to traditional warfarin regimens. Measuring the prevalence of TEs may clarify whether there is a need for thromboprophylaxis in patients with GCA. The aim of this study was to investigate the lifetime prevalence of TEs in patients with GCA along with the prevalence of risk factors associated with venous thromboembolism or stroke.

Methods: Electronic medical records (EHRs) of patients who fulfilled the following criteria were reviewed: A. Previous temporal artery biopsy (whether positive or negative) with or without non-invasive imaging of the temporal arteries and B. establishment of giant cell arteritis based on ICD-10 codes, the ACR criteria, and the clinical determination of the treating rheumatologist. Relevant data were abstracted by two trained team members out of the inpatient and outpatient (EHRs). The main outcome of interest was the earliest radiologically verified acute TE on record, including stroke, deep vein thrombosis or arterial thromboembolism, excluding prior myocardial infarction. Data regarding common thromboembolic risk factors were extracted, including concurrent COVID-19 infection, active or 5-year history of cancer and/or verified thrombophilia. In patients with stroke, relevant risk factors including atrial fibrillation, prior myocardial infarction, peripheral arterial disease, eGFR < 45 ml/min/m2, and prior revascularization procedures were identified if present.

Results: The records of 70 patients with confirmed GCA were reviewed (Mean age 75.6 years, 71% female, 9% Asian/10% African American, 44% Caucasian, 37% Race not reported). Lifetime prevalence of  TE was 14% (10/70), consisting of either stroke (9%, 6/70) or VTE (6% 4/70). Of those patients with TE, 1 patient with VTE did not have any other identifiable risk factors. The incidence rate within the 3-month period before or after the time of diagnosis was  67% for stroke events and 50% for VTE. For those 3 patients with stroke and no other identifiable risk factors, the stroke occurred within 3 months of the GCA diagnosis and two of them had evidence of anterior ischemic optic neuropathy, interestingly without complaints of headache.

Conclusion: The high lifetime prevalence of TEs in patients with GCA in this retrospective study is consistent with prior studies and further demonstrates a clustering of TEs around GCA diagnosis, especially for patients without other identifiable risk factors. This study can serve as the basis for designing future observational studies, while making the case for investigations into the efficacy of thromboprophylaxis around the time of GCA diagnosis and beyond.


Disclosures: I. Koulas: None; N. Tsaftaridis: None; I. Ilic: None; J. Jnani: None; A. Spyropoulos: AstraZeneca, 6, Bayer, 6, Boehringer-Ingelheim, 5, Bristol-Myers Squibb(BMS), 6, Janssen, 5, 6, Pfizer, 6, Sanofi, 6; L. El Khoury: None.

To cite this abstract in AMA style:

Koulas I, Tsaftaridis N, Ilic I, Jnani J, Spyropoulos A, El Khoury L. An Observational Study of Lifetime Prevalence of Thromboembolism Among Patients with Giant Cell Arteritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/an-observational-study-of-lifetime-prevalence-of-thromboembolism-among-patients-with-giant-cell-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-observational-study-of-lifetime-prevalence-of-thromboembolism-among-patients-with-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology